Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes this is big news! It would even better if they where announcing patient 250 has been enrolled! I do not think this is going to cause to much of a jump because we have 249 patients left to go!
Yes you are right! The shorts also have a hold of this stock and manipulate the PPS all the time!
NeoStem Announces First Patient Randomized in Pivotal Phase 3 Melanoma Immunotherapy Clinical Trial
By GlobeNewswire, April 29, 2015, 04:01:00 PM EDT
Vote up
loading
A A A
The Intus Trial is Being Conducted Under a Special Protocol Assessment (SPA) With a Primary Endpoint of Overall Survival
NEW YORK, April 29, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the randomization of the first patient in the Intus Phase 3 clinical trial investigating the efficacy of the Company's patient-specific targeted cancer immunotherapy candidate NBS20 (USAN = eltrapuldencel-T) in patients with stage III recurrent or stage IV metastatic melanoma. The Intus trial has been granted a Special Protocol Assessment (SPA) by the U.S. Food and Drug Administration (FDA), which permits this trial, if successful, to be the sole pivotal trial necessary for registration. The NBS20 development program has also been granted Orphan Drug and Fast Track designations by the FDA.
The Intus trial is based on consistent, compelling results from two Phase 2 trials in identical patient populations evaluating the therapeutic vaccine that has become NBS20. The more recent of the two trials was a randomized trial comparing NBS20 to injections of autologous irradiated (inactivated) tumor cells in 42 patients. At two years, survival was 72% compared to 31% for control patients (p=0.007), which was consistent with the previous Phase 2 trial's findings in which NBS20 demonstrated 73% two-year survival in 54 patients, with a median survival of five years. Toxicity was minimal and consisted of mild to moderate local injection site reactions of the type normally associated with injections of GM-CSF (a protein secreted by immune cells that helps stimulate other immune cells to promote immune defenses against disease).
"The randomization of the first patient in the pivotal Phase 3 trial for NBS20 represents the achievement of a significant milestone for NeoStem, marking our transformation into a Phase 3 immuno-oncology company. We are now part of a select group of immunotherapy companies at such an advanced clinical development stage," said Dr. David J. Mazzo, Chief Executive Officer of NeoStem.
The Intus study is a multi-national, randomized, double-blind, placebo-controlled Phase 3 clinical trial in which stage III recurrent or stage IV metastatic melanoma patients will be randomized in a 2:1 ratio to receive either NBS20 (autologous dendritic cells loaded with antigen from self-renewing, proliferating autologous tumor cells in GM-CSF) or a control treatment (peripheral blood mononuclear cells obtained from apheresis product in GM-CSF). The study is expected to randomize 250 eligible patients across approximately 50 sites internationally (US, Canada, Australia, New Zealand and, potentially, select countries of the EU); each patient will receive subcutaneous injections once weekly for three consecutive weeks, and then once monthly for five months.
"We are pleased to take another step in our efforts to demonstrate the efficacy of this patient-specific therapy in the hope of improving long-term survival of patients with metastatic melanoma, especially given approval of recent therapies that have yielded strong response rates without demonstrating substantial impact on survival," said Dr. Robert Dillman, Vice President, Oncology of NeoStem and founder of the NBS20 technology.
In addition to metastatic melanoma, the platform technology on which NBS20 is based is potentially applicable across multiple solid tumor types, including advanced lung, colon, kidney, ovarian and hepatocellular carcinomas, and glioblastoma multiforme—indications that collectively lead to more than 200,000 deaths in the United States each year.
For more information on the Intus Study please visit www.theintusstudy.com or www.clinicaltrials.gov/ct2/show/NCT01875653.
About Metastatic Melanoma
Melanoma, which originates in pigment-producing cells known as melanocytes, is the most lethal form of skin cancer. Melanoma is often caused by unrepaired DNA damage to skin cells from UV radiation. Patients who have progressed to stage IV melanoma have a cancer that has metastasized—or spread—to distant sites in the body such as the lymph nodes, lungs, liver or brain. As a result, advanced melanoma is exceedingly difficult to treat, with a five-year survival rate of approximately 15%. There are 20,000 estimated new cases of metastatic melanoma, and an estimated 10,000 deaths from metastatic melanoma, each year in the United States.
Treatments for stage IV melanoma are typically directed at slowing the growth of the cancer and prolonging survival. Current treatment options include radiation, chemotherapy, surgical resection, immunotherapy, or a combination approach. Unfortunately, current therapies have had limited impact on long-term survival for most patients. Even with the newer targeted therapies (anti-checkpoint inhibitors and specific enzyme inhibitors), half of patients with metastatic melanoma still die within 13 to 17 months from the start of such treatment. Administering certain anti-melanoma drugs at higher doses or in combinations may be more effective, but often results in more severe side effects.
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell-based individualized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immuno-oncology, ischemic repair and immunomodulation) with a lead, late-stage clinical program for each. The combination of a rich therapeutics pipeline and an externally recognized in-house center for cell therapy process development and manufacturing has created an organization with unique capabilities for accelerated and efficient product development. www.neostem.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-oncology Program (especially its Intus Phase 3 clinical trial for metastatic melanoma), Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT, as well as its efforts to expand its capabilities into the cell therapy tools market. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 2, 2015, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.
Read more: http://www.nasdaq.com/press-release/neostem-announces-first-patient-randomized-in-pivotal-phase-3-melanoma-immunotherapy-clinical-trial-20150429-01273#ixzz3YjUz8iDP
Cryoport Supports NeoStem''s Intus Study for the Treatment of Metastatic Melanoma
By PR Newswire, April 29, 2015, 08:30:00 AM EDT
Vote up
loading
A A A
LAKE FOREST, Calif., April 29, 2015 /PRNewswire/ -- Cryoport, Inc. (OTCBB:CYRX) ("Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that the Company is supporting NeoStem, Inc.'s (NASDAQ:NBS) Intus Study to evaluate its lead cancer immunotherapy, NBS20, for the treatment of metastatic melanoma.
NeoStem, a biopharmaceutical company, is developing an autologous immunotherapy that uses a patient's own tumor cells to maximize the immune system's ability to identify and eliminate the cancer initiating cells that NeoStem believes are capable of reconstituting and developing new tumors. The proposed therapeutic combines a patient's own purified and irradiated cancer cells with specialized immune cells, educating the immune cells to destroy the cancer initiating cells from which tumors arise. The Intus Study for the treatment of metastatic melanoma has received Special Protocol Assessment and the program has received Fast Track and Orphan Drug Designations from the US Food and Drug Administration ("FDA").
Cryoport's best-in-class cryogenic logistics solution is providing comprehensive support for NeoStem's Intus Study, which is advancing to a Phase 3 trial. The Company is an important partner to the NBS20 development program as it launches the multi-center trial and provides access to enrolled patients to the cryopreserved, cell-based therapy that could potentially treat the rapid progression of the deadly cancer.
David J. Mazzo, Ph.D., Chief Executive Officer of NeoStem, commented, "At NeoStem, we are dedicated to preserving and enhancing human health through the development of novel cell-based individualized therapies like our lead Phase 3 program in immuno-oncology, the Intus Study, targeting the treatment of late-stage melanoma. Cryoport plays an important role in NBS20 development by supporting the Intus Study with the cryopreserved delivery of NBS20 to our clinical sites in the United States. They have been instrumental in facilitating trial access to our patients and we welcome the opportunity to further strengthen and expand our relationship with the company as we require additional support."
Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "We are pleased to be able to support NeoStem with their efforts in developing innovative cell-based personalized therapies. Our validated cryogenic logistics solutions will maintain the integrity of the Intus trial as it advances through the regulatory pathway that has been set by the FDA. We are actively supporting the distribution of NBS20 and will eagerly continue to support NeoStem as it advances its clinical trials."
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world's largest shipping companies controlling more than 85% of the world's air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Logo - http://photos.prnewswire.com/prnh/20140401/NY95107LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/…/cryoport-supports-neostems-intu…
SOURCE Cryoport, Inc.
Read more: http://www.nasdaq.com/…/cryoport-supports-neostems-intus-st…
Thank You!
Read this: http://news.yahoo.com/fda-staff-cite-concerns-over-amgens-cancer-vaccine-124252108--finance.html
Then see this is are endpoint so they will have nothing to say about nbs endpoint, we have the endpoint they want!!! YAHHOOOO
https://clinicaltrials.gov/ct2/show/NCT01875653?term=cancer&lead=neostem&rank=1
Article Dr, Dillman http://online.liebertpub.com/doi/10.1089/cbr.2014.1805
NeoStem's Lead Immuno-oncology Product Candidate, NBS20, Receives ATMP Classification from the European Medicines Agency
New York (April 27, 2015) - NeoStem, Inc. (NASDAQ:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today that the European Medicines Agency (EMA) has classified the Company's lead immuno-oncology product candidate, NBS20, as an Advanced Therapeutic Medicinal Product (ATMP). ATMP classification, which is approved by the Committee for Advanced Therapies (CAT), was established to regulate cell and gene therapy and tissue engineered medicinal products, support development of these products and provide a benchmark for the level of quality compliance for pharmaceutical practices. As a designated ATMP product, NBS20 would follow the Centralized Procedure through the European Medicines Agency and benefit from a single evaluation and authorization process. Additional benefits established through the ATMP regulation include pathways for Scientific Advice and significant fee reductions for such advice.
NBS20 is the Company's patient-specific targeted cancer immunotherapy candidate being investigated in the Intus Phase 3 trial in patients with stage III recurrent or stage IV metastatic melanoma. Treatment of metastatic melanoma continues to be an unmet medical need globally. In Europe, over 20,000 deaths from melanoma were estimated in 2008, approximately twice the number of recent estimates of annual deaths in the US.
NeoStem's global Intus trial has been granted a Special Protocol Assessment (SPA) by the U.S. Food and Drug Administration (FDA). In addition, NBS20 has US Orphan Drug and Fast Track designations by FDA. Patient screening began in the first quarter of 2015 and the Company anticipates the randomization of the first patient in the Intus trial in the second quarter of 2015.
"We thank the EMA for this validation of the technically advanced nature of NBS20 as a therapy for melanoma. The ATMP classification will facilitate discussions with EMA as part of our strategy to seek product registration in the EU," said Dr. David J. Mazzo, Chief Executive Officer of NeoStem. "This designation sets NBS20 apart from the immunologic approaches being developed to treat melanoma based on inhibition of a single target and emphasizes its ability to address the complex and multiple tumor-specific targets found on each patient's metastatic tumors."
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell based individualized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immuno-oncology, ischemic repair and immunomodulation) with a lead, late-stage clinical program for each. The combination of a rich therapeutics pipeline and an externally recognized in-house center for cell therapy process development and manufacturing has created an organization with unique capabilities for accelerated and efficient product development. www.neostem.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT, as well as its efforts to expand its capabilities into the cell therapy tools market. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 2, 2015, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.
LOL that is just about where I am at also! I just believe so much in there science or I would have been gone long ago!
I think it all has to do with financing or a partnership! If they have to sell stock to raise money the PPS will go down and they are in need of money! The CEO has stated several times he is going to try to partner to get the needed money BUT that has not happened yet! There has been no really big grants come in either. Soon as the problem is solved this stock will shoot up! It has Phase3 trails right now and phase 2 which are really good! I truly believe in there science and I have bought stock with them for 3 years now and I am down money(just being honest) I will buy more in a minute just as soon as this problem is resolved! If I where not down already the price is a very good buy when you look ito what they all have!
I would be thrilled for $10
NBS mentioned here!(From THE STREET)
3 Breakout Stocks Under $10 for Your Trading Radar
By Roberto Pedone Follow | 04/23/15 - 01:58 PM EDT
Neostem
Neostem (NBS - Get Report), a clinical-stage biopharmaceutical company, develops cell-based therapeutics in the U.S. This stock is trading up 4.8% to $3.02 in Thursday's trading session.
Thursday's Range: $2.88-$3.04
52-Week Range: $2.34-$7.23
Thursday's Volume: 199,000
Three-Month Average Volume: 341,345
From a technical perspective, NBS is spiking higher here right above some near-term support at $2.70 with lighter-than-average volume. This jump to the upside on Thursday is starting to push shares of NBS within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will hit if NBS manages to take out some near-term overhead resistance levels at $3.07 to $3.14 with high volume.
Traders should now look for long-biased trades in NBS as long as it's trending above Thursday's intraday low of $2.88 or above more near-term support at $2.70 and then once it sustains a move or close above those breakout levels with volume that registers near or above 341,345 shares. If that breakout develops soon, then NBS will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day moving average of $3.39 to $4 a share.
http://www.thestreet.com/story/13124312/3/3-breakout-stocks-under-10-for-your-trading-radar.html
My friend Tanya posted this on my facebook and I thank her for this and wanted to share it with anybody interested in a FREE STEM CELL wallchart! It tells how the cells develop what or how they turn into! http://www.stemcell.com/Home/Forms/Wallcharts/Wallchart%20Directed%20Differentiation%20of%20Pluripotent%20Stem%20Cells.aspx?&utm_source=twitter&utm_medium=social&utm_campaign=psc_directeddiffwallchart
NBS will be busy tomorrow! We have 2 events happening.
INTERPHEX
April 22, 2015 - 2:00 PM ET Jacob Javits Center, New York, New York • Presenter: Dr. Robert Preti, Chief Scientific Officer • Topic: Development by Design: A Strategy to Support Commercial Success
American Association for Cancer Research Annual Meeting April 22, 2015 - 8:00 AM ET Pennsylvania Convention Center, Philadelphia, Pennsylvania • Presenter: Dr. Andrew N. Cornforth, Manufacturing Director • Poster: Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma - See more at: http://www.neostem.com/media/events/#sthash.hvpFH9oR.dpuf
NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma
Amendment Adds Dedicated NeoStem Facilities and Personnel
New York (April 20, 2015) -- NeoStem, Inc. (NASDAQ:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the expansion of manufacturing services under an existing Services Agreement between its wholly-owned subsidiary, PCT, and Kite Pharma, Inc. (NASDAQ:KITE) (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer.
Under the terms of the original agreement, PCT and its center of excellence for cell therapy process development, engineering and manufacturing, provided development and manufacturing services for Kite's lead eACT™ clinical development program. These services included technology transfer, process development, qualification and implementation of the manufacturing process. Under the expanded Services Agreement, Kite will receive these services through increased facilities and personnel at PCT's Mountain View, CA location that are contractually dedicated to Kite.
"We look forward to continuing our mutually beneficial partnership with Kite and to offering manufacturing service for the important cell therapy that they plan to advance toward the commercial market," said Dr. Robert A. Preti, Chief Scientific Officer of NeoStem and President of PCT. "The expansion of NeoStem's arrangement with Kite allows us to grow our Mountain View facility and to continue providing innovative, reliable and high quality manufacturing expertise to cell therapy developers who are researching potentially life-changing treatments for patients across many therapeutic areas."
"We are pleased that we have expanded our relationship with Kite and look forward to continuing to provide them with premium specialized immunotherapy manufacturing services. This arrangement with Kite will serve as a model for future collaborations between PCT and its clients," said Dr. David J. Mazzo, NeoStem's Chief Executive Officer. "We have valued PCT's expertise, manufacturing facilities, and services, and we look forward to a continued productive relationship with them," said Dr. Arie Belldegrun, Chairman, President and Chief Executive Officer of Kite.
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell based individualized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immune-oncology, ischemic repair and immunomodulation) with a lead, late-stage clinical program for each. The combination of a rich therapeutics pipeline and an externally recognized in-house center for cell therapy process development and manufacturing has created an organization with unique capabilities for accelerated and efficient product development. www.neostem.com
This has been added for you to watch from the Alliance for Regenerative Medicine 3rd Annual Regen Med Investor Day – Archived Webcast - See more at: http://www.neostem.com/media/events/#sthash.d0ouBhiV.dpuf
This is from April 15th 2015
Carl Ichan thinks Neostem is good or why out of all the Stem Cell companies would he pick NeoStem?
Mount Sinai researchers who received an $8.8 million grant Health Pulse Subscription Needed: from the New York State Cell Science Program in January have forged an alliance with two companies to help accelerate their project beyond the lab. NeoStem, a Manhattan company, and Alameda, Calif.-based AllCells will contribute to a 10-person team tasked with moving the research to clinical trials. The group is led by Dr. Ronald Hoffman, professor of medicine, hematology and medical oncology at the Icahn School of Medicine. It has four years, starting July 1, to accomplish its goal of expanding the number of stem cells collected in cord blood so that the number of cells is adequate to treat adults with chemotherapy-resistant blood cancers and other genetic diseases. Dr. Hoffman has been working on cord-blood expansion since the 1980s, and his team has developed a technique effective in the lab. NeoStem and AllCells will help perform the technique on a larger scale while adhering to federal manufacturing standards. "My concept was, since we're not an industrial corporation, it was probably best to interact with companies that are used to dealing with cellular products in an industrial fashion," Dr. Hoffman said, adding that the collaboration is unique for academic research, which can be "a very individualistic type of operation."
Whole story here>> http://www.crainsnewyork.com/article/20150415/PULSE/150419928/gnyha-1199-seiu-confront-labor-pain
On NeoStem site they have now updated the investor presentation! Everybody should go threw it and take a look. On slide 5 look at all the new clients listed! http://www.neostem.com/investors/overview/
Don't forget PCT!
PCT Conference Attendance >
International Pharmaceutical Expo (Interphex)
April 21 - 23, 2015 / New York, New York / website
Dr. Robert Preti, President & Chief Scientific Officer, will present on "Development by Design: A Strategy to Support Commercial Success".
http://pctcelltherapy.com/connect/pct-conferences/
NBS will be busy today!
We have 2 conferences going on!
Needham & Company’s 14th Annual Healthcare Conference April 15, 2015 - 3:00 PM ET The Westin Grand Central Hotel, New York, New York • Presenter: Dr. David Mazzo, Chief Executive Officer • Topic: Company Presentation To view the webcast follow the external link to the webcast page and sign-in. The webcast will be available for 90 days following the presentation.
Crain’s ‘Business Of’ Series: Life Sciences April 15, 2015 - 8:30 AM ET John Jay College of Criminal Justice, New York, New York • Panelist: Dr. Robin L. Smith, Executive Chairman • Topic: Life Sciences, Economic Diversification and Job Growth
- See more at: http://www.neostem.com/media/events/#sthash.WLXNFFDT.dpuf
I think everyone is hoping for a partnership, but the need for financing may come first! If I did not already own NBS and know what there are capable of I think I would be gun shy jumping in right now. I hope to God we partner soon and yes Baxter would be perfect. But NBS does not even put out good PR to let investors know what is going on. There are plenty of articles I posted on here you have not seen anywhere else unless you googled the subject or searched. Why isn't NBS getting these articles out, if people seen them they would probably be more apt to invest.
This is very interesting! I guess maybe it was made for a school project BUT watch it!
Oh I agree Andy E! My PPS right now is a little higher than that! I have bought and sold NBS a few times and made money to buy more shares. I always planned on NBS being a long time investment BUT in the mean time when it would shoot up I would sell let it go down and then buy back at a lower price more shares. Last time I bought it did not go back up which is fine for now because I have been long on NBS and will continue to be. I think the company needs more PR! I see stuff posted all the time about NBS that never even fits there facebook page or there company page. Everybody knows you have to get the news out to investors!
http://link.brightcove.com/services/player/bcpid3591057483001?bckey=AQ~~,AAABsp7SeIE~,lLxZotOlf8tVBhGxPc4jokrVkXRhGVw3&bctid=4167312283001 Here is a short video from April 10th conference!
I believe also that is what has brought our PPS value down also. Unlike you LOL I do not want to be at $2,50 again, LOL! I am in at a much higher price and am really tired of this stock going up and down. Hurry and rebuy and let it hit the moon Alice Oh I mean Jeffsmom!lol Either way good luck!
Baxter would be perfect! I also think one is in the makings at the present time, which one I do not know.
Neostem, Inc. (NASDAQ:NBS) has traded 1.4% of the total shares outstanding in the last 20 days. The average daily volume for the preceding 20 days is 537,480shares. The short ratio for the counter is 10.47. The short interest has changed by -0.19% in the past 1 month. The 3-month % change in short interest is -3.87%. In the past month, the total shorts are equal to 0.07 times the outstanding shares. A negative %change in the short interest reflects that bears are losing grip while a positive %change in the short interest points to a strong bearish pull over.
Remember NBS is here today!
April 10, 2015 - 5:10 PM ET Sheraton New York Times Square Hotel, New York, New York • Presenter: Dr. Robert O. Dillman, Vice President, Oncology • Poster: INTUS: Randomized Phase III Trial of Patient-specific Therapeutic Vaccine (NBS20) in Patients Who Have Had Metastatic Melanoma
http://www.healio.com/meeting/hemonctodaymelanoma/home
Honestly IMO I think it is because we have not secured enough in financing! I think everybody is worried about a stock sale to raise money.(I would be a liar if I said I was not worried) We have gotten a small amount in grants but they are hoping for BIGGER grants and a PARTNERSHIP! If you are going to be a long time holder and believe in the science and procedures of NBS, the best time to get in is before a partnership. If you plan on day trading I can not help you there. I know NBS has a good team in management and has mentioned several times they want to go with none dilutive financing which I believe they are trying to do with grants or a partnership. If they wanted to do a stock sale to raise money I actually believe they would have done it when we where in the $4 range and higher. We are in a good phase 2 with good results on ARM, We have a phase 3 in oncology that will be life changing. So I think we will partner up. Do your DD about what we have going on, boards are usually not the right place because they are opinion based. Read the articles here though they are very helpful and are fact based! GOOD LUCK TO YOU!!
Here is a good article>> http://www.thelifesciencesreport.com/pub/na/why-investors-shouldnt-worry-about-explosive-new-drug-pricing-maxims-jason-kolbert
Here is the part I like!>>
JK: I feel like I've already seen proof of concept in Mesoblast's product, Athersys' product and NeoStem's product, NBS10 (autologous, bone marrow-derived, CD34+ /CXCR4+ enriched cells). By default, I expect the Pluristem product, PLX-PAD (full-term placenta-derived adherent stromal cells), to work. PLX-PAD is a heterogeneous mixture of cells, which differs from Mesoblast's mesenchymal precursor cells and Athersys' MultiStem, which are both homogeneous groups of cells. The company's lead indications are peripheral artery disease and muscle injury, including that associated with surgery for total hip replacement.
TLSR: You've mentioned NeoStem a couple of times. Last November the company reported top-line results in its Phase 2b PreSERVE-AMI trial of NBS10 in ST segment elevation myocardial infarction (STEMI). It did not meet its primary endpoint of cardiac perfusion. Yet you see proof of concept. What do you mean?
JK: The STEMI trial showed a tremendous mortality benefit and an improvement in virtually every secondary measure. That improvement, by the way, was recently affirmed at the American College of Cardiology, when Dr. Arshed Quyyumi, the principal investigator, presented the 12-month follow-up data. What I see in the NeoStem PreSERVE-AMI trial is a very successful study. The bears will say one of its primary endpoints, perfusion, didn't show a sufficiently low p-value. But perfusion is not an approvable endpoint in a pivotal trial anyway. Mortality is, and NeoStem has shown a mortality benefit.
If a stock is cut in half on bad Phase 2 data, whether NeoStem or Athersys, I would absolutely be buying more, because I don't believe the Phase 2 endpoints are significant in either trial. The Phase 2 data that NeoStem reported were good data. What investors have to understand is that sometimes Phase 2 data won't give a low enough p-value, but does give information on what a company needs to be successful in Phase 3. If, on the other hand, the Athersys or NeoStem data show no trends, and no difference whatsoever between placebo and the active arm, that would be very disappointing and would suggest something is not right
NeoStem Announces Extension of Study Under Grant from California Institute of Regenerative Medicine (CIRM) to Fund Research of Retinal Disease?
NeoStem Announces Extension of Study Under Grant from California Institute of Regenerative Medicine (CIRM) to Fund Research of Retinal Disease
New York, NY (April 9, 2015) - NeoStem, Inc. (NASDAQ:NBS), a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today the extension of its study for retinal disease under a 2014 Early Translational grant from the California Institute of Regenerative Medicine for research leading to the development of a treatment for retinal diseases, including macular degeneration and retinitis pigmentosa.
Under the $4 million grant made to the University of California, Irvine, NeoStem is entitled, through a subaward, to $1 million of new funds adding to the original $0.5 million awarded . The goals of the research are to generate three-dimensional retinal tissue, to investigate the ability of adult induced pluripotent stem cells to restore sight in rodent models of retinal degeneration and to make eventual preparations for clinical use of the tissue.
The grant supports a three-year study led by Dr. Hans S. Keirstead, President of NeoStem Oncology, and Dr. Magdalene J. Seiler, Project Scientist V at the University of California, Irvine and its Sue & Bill Gross Stem Cell Research Center.
"This study exemplifies our commitment to utilizing non-dilutive funding sources for discovery programs exploring application of our technologies in other indications. A self-sustaining development pipeline depends on the generation of new development programs that are reasonable in terms of size of opportunity and clinical investment," said Dr. David J. Mazzo, Chief Executive Officer of NeoStem.
In the first year of the study, NeoStem fulfilled its primary goal of reproducibly generating retinal pigment epithelium (RPE) and layered retinal progenitor tissue, which include progenitors of the major retinal cell types including photoreceptors. This success enables the rest of the study, which will focus on transplantation and testing of these tissues in rodent models of retinal degeneration.
Approximately 11 million people in the United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050. Estimates of the global cost of visual impairment due to age-related macular degeneration is $343 billion, including $255 billion in direct health care costs.
You are right! NBS is really starting to move, I hope we can hold $3 and start the move up from here!
Here's a good start, and we should stay tuned for much more to come.
“We are grateful to NYSTEM for providing a unique opportunity to move our discoveries in the laboratory to a clinical setting,” said Dr. Hoffman. “We are able to build upon 30 years of work to develop new treatment options for our patients.”
“This award creates a synergistic environment between academic centers and biotechnology firms. And ensures promising research continues to keep progressing,” said Dr. Hoffman. “Our partners NeoStem and AllCells are vital contributors in this next phase of research. We are very excited about the journey ahead.”
http://www.mountsinai.org/about-us/newsroom/press-releases/mount-sinai-receives-88-million-grant-to-further-stem-cell-research
Hold tight the PPS will start to rise! Here is a article dated April 6 2015 http://www.newsmax.com/Health/Health-News/cancer-vaccine-survival-progression/2015/04/06/id/636745/ and here is the total article they are talking about http://online.liebertpub.com/doi/10.1089/cbr.2014.1805 We will see the PPS start to rise slowly. Remember this is a great company, great people we just need a chance to show the science behind everything works and that is starting to happen NOW!!!!!
PCT Conference Attendance >
International Pharmaceutical Expo (Interphex)
April 21 - 23, 2015 / New York, New York / website
Dr. Robert Preti, President & Chief Scientific Officer, will present on "Development by Design: A Strategy to Support Commercial Success".
World Stem Cells Regenerative Medicine Congress 2015
May 20-22, 2015 / London, UK / website
Dr. Robert Preti, President & Chief Scientific Officer, will present.
ISCT 2015 Annual Meeting
May 27-30, 2015 / Las Vegas, NV / website
PCT to sponsor and exhibit.
NBS has 6 new events for April!>>>
NeoStem to Present at Multiple April Conferences
New York, April 6, 2015 - NeoStem, Inc. (NASDAQ:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell-based personalized medicine therapies, announced today that the Company's management and experts will present at multiple conference in April.
HemOnc Today Melanoma and Cutaneous Malignancies
•Date and Time: Friday, April 10, 2015, 5:10 PM ET
•Venue: Sheraton New York Times Square Hotel, New York, New York
•Website: www.healio.com/meeting/hemonctodaymelanoma/home
•Presenter: Dr. Robert O. Dillman, Vice President, Oncology
•Poster: INTUS: Randomized Phase III Trial of Patient-specific Therapeutic Vaccine (NBS20) in Patients With Metastatic Melanoma
Crain's 'Business Of' Series: Life Sciences
•Date and Time: Wednesday, April 15, 2015, 8:30 AM - 10:00 AM ET
•Venue:John Jay College of Criminal Justice, New York, New York
•Website:http://www.crainsnewyork.com/events.../details/4/3256496
•Panelist: Dr. Robin L. Smith, Executive Chairman
•Topic:Life Sciences, Economic Diversification and Job Growth
Needham & Company's 14th Annual Healthcare Conference
•Date and Time: Wednesday, April 15, 2015, 3:00 PM ET
•Venue: The Westin Grand Central Hotel, New York, New York
•Website: ://www.needhamco.com/.../InstitutionalSa.../Conferences.aspx
•Presenter: Dr. David Mazzo, Chief Executive Officer
•Topic: Company Presentation
•Webcast:www.neostem.com/investors/investor-events/
American Association for Cancer Research Annual Meeting
•Date and Time: Wednesday, April 22, 2015, 8:00 AM ET
•Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania
•Website: www.aacr.org/Meetings/Pages/MeetingDetail.aspx...
•Presenter: Dr. Andrew N. Cornforth, Manufacturing Director
•Poster: Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma
Interphex
•Date and Time: Wednesday, April 22, 2015, 2:00 PM ET
•Venue: Jacob Javits Center, New York, New York
•Website: www.interphex.com
•Presenter: Dr. Robert Preti, Chief Scientific Officer
•Topic: Development by Design: A Strategy to Support Commercial Success
Stem Cell Summit 2015
•Date and Time: Tuesday, April 28, 2015, 4:05 PM ET
•Venue: Hyatt Regency, Boston, Massachusetts
•Website: www.gtcbio.com/conferences/stem-cell-summit-agenda
•Presenter: Dr. Hans Keirstead, President, NeoStem Oncology
•Topic: Immunotherapy - Revolution in Cancer
Home - HemOnc Today Melanoma CME Meeting
You're invited to join more than 250 colleagues and...
healio.com
Happy Easter and Pray for our troops!
Here is another story! Just great! http://www.theneweconomy.com/business/fighting-cancer-with-innovative-immunotherapy-techniques
Here's an excellent interview of Neostem's CEO Dr.David Mazzo by Maxim's Jason Kolbert. At the Alliance for Regenerative Medicine Conference last week. Was just put out on Youtube 16 hrs. ago!